Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aurora kinase A pseudogene 1 is a human pseudogene located on chromosome 1q41. It is transcribed as a long non-coding RNA (lncRNA) and shares sequence similarity with the protein-coding Aurora kinase A gene. While it does not produce a functional kinase enzyme, AURKAP1 is upregulated in several cancers, including head and neck squamous cell carcinoma and hepatocellular carcinoma. Higher expression levels are associated with increased genome instability, aggressive tumor phenotype, and worse response to radiotherapy. AURKAP1 functions as a competitive endogenous RNA, sponging microRNAs such as miR-182, miR-155, and miR-142, thereby influencing cell cycle regulation, DNA repair pathways, cell proliferation, and tumor invasion. Current evidence supports its potential utility as a molecular diagnostic or prognostic biomarker, but it is not considered a direct therapeutic target due to its pseudogene status.
Drugs do not directly target this pseudogene; its functional impact is via regulation of gene expression and interaction with microRNAs (e.g., sponging miR-182, miR-155, and miR-142).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aurora kinase A pseudogene 1 (AURKAP1).